Physician profile
Lisandy Aleman
NPI 1891146916
$1,597.01
in general payments reported to CMS, 2019-2025
27 companies · $179 in 2025
The $179 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $411 · 2022: $506 · 2023: $136 · 2024: $365 · 2025: $179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $680.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $680.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $300.02 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $180.06 | 2022-2025 | Relistor |
| Scilex Pharmaceuticals INC. | $124.99 | 2021-2024 | Ztlido |
| Heron Therapeutics, INC. | $121.84 | 2024 | Zynrelef, Aponvie |
| Electronic Waveform Lab, INC. | $120.21 | 2024-2025 | |
| Radius Health, INC. | $77.40 | 2021-2022 | |
| Redhill Biopharma INC. | $76.56 | 2021 | |
| Stryker Corporation | $68.43 | 2025 | Pangea |
| Almatica Pharma LLC | $59.59 | 2022-2023 | Loreev Xr |
| Depuy Synthes Sales INC. | $59.22 | 2022-2023 | Orthovisc, Monovisc |
| Collegium Pharmaceutical, INC. | $42.87 | 2021 | |
| Smith+Nephew, INC. | $41.79 | 2022-2024 | Pico 14 |
| Abbvie INC. | $38.22 | 2022 | |
| Mimedx Group, INC. | $29.90 | 2025 | |
| Pacira Therapeutics, INC. | $29.59 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanara Medtech INC. | $26.53 | 2023 | Celleraterx |
| Vericel Corporation | $25.39 | 2022 | |
| Horizon Therapeutics Plc | $24.93 | 2022 | |
| Abbott Laboratories | $24.00 | 2024 | Proclaim |
| Pacira Pharmaceuticals Incorporated | $21.21 | 2023 | Zilretta |
| Kowa Pharmaceuticals America, INC. | $16.65 | 2022 | |
| Boston Scientific Corporation | $16.07 | 2023 | Epic Vascular |
| Grt US Holding, INC. | $15.86 | 2022 | |
| Nevro Corp. | $15.35 | 2022 | |
| Kerecis Limited | $15.21 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Vertex Pharmaceuticals Incorporated | $13.72 | 2024 | |
| Avanos Medical | $11.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisandy Aleman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.